Physician profile
Simin Ovais
NPI 1306957691
$6,246.44
in general payments reported to CMS, 2019-2025
43 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $452 · 2021: $1,099 · 2022: $1,013 · 2023: $917 · 2024: $1,216 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214 · Consulting Fee: $21.36 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,213.84 |
| Consulting Fee | $21.36 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,211.24 | 2020-2025 | |
| Pfizer INC. | $625.91 | 2019-2025 | |
| Novo Nordisk INC | $522.63 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $474.21 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbott Laboratories | $458.50 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $408.40 | 2022-2025 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $336.80 | 2019-2022 | |
| Allergan, INC. | $235.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $188.19 | 2019-2025 | Airsupra, Breztri, Saphnelo |
| Lilly USA, LLC | $131.36 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $129.77 | 2021-2025 | |
| Amarin Pharma, INC. | $111.55 | 2021 | |
| Sunovion Pharmaceuticals INC. | $107.79 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $104.54 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $91.10 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simin Ovais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.